A drug being developed by Boehringer Ingelheim for COVID-19 and reinvented as a potential therapy for kidney disease has now hit the mark in a phase 2 trial. TRPC6 inhibitor apecotrep (BI 764198), ...
Multifactorial diseases pose a significant global health challenge, impacting economically developed nations with conditions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results